| P |
|
P2RY12 RECEPTOR POLYMORPHISMS (SNPS) IN PATIENTS WITH A HISTORY OF MYOCARDIAL INFARCTION
|
| Murugesan G., Zhang L., Jang S., Kaldus T., Barnard J., Wang Q., Gaussem P., Topol E.J., Kottke-Marchant K. |
| |
|
P2X1 RECEPTORS AS NEW REGULATORS OF NEUTROPHIL LIFE SPAN
|
| Faccinetto C., Lecut C., Jacobs N., Bours V., Oury C. |
| |
|
P2Y12 ANTAGONIST COMPLEMENTARY TO ASPIRIN THERAPY IS SUPERIOR TO ASPIRIN ALONE IN PATIENTS AFTER CARDIOSURGERY OPERATIONS
|
| Kuliczkowski W., Golanski J., Golanski R., Iwaszkiewicz A., Polonski L., Watala C. |
| |
|
P2Y12 BLOCKADE BY PRASUGREL ACTIVE METABOLITE YIELDS COMPLETE INHIBITION OF P2Y12-MEDIATED AMPLIFICATION OF PLATELET RESPONSES
|
| Judge H.M., Buckland R.J., Sugidachi A., Jakubowski J.A., Storey R.F. |
| |
|
PAEDIATRIC REFERENCE RANGES FOR COAGULATION DIAGNOSTICS
|
| Halimeh S., Kappert G., Rott H., Trobisch H. |
| |
|
PAEDIATRIC STROKE
|
| Kirkham F.J., Kenet G., Ganesan V., DeVeber G., Nowak-Gottl U. |
| |
|
PAI-1 GENE 4G/5G GENOTYPE AS AN ADDITIONAL RISK FACTOR IN PATIENTS WITH THROMBOSIS: A RETROSPECTIVE COHORT STUDY
|
| Guglielmone H., Minoldo S., Jarchum G. |
| |
|
PAI-1 GENE HAPLOTYPES ARE ASSOCIATED WITH MYOCARDIAL INFARCTION OCCURRENCE IN NON SMOKERS: THE HIFMECH STUDY
|
| Morange P.E., Saut N., Alessi M.C., Yudkin J.S., Margaglione M., Di Minno G., Hamsten A., Humphries S.E., Juhan-Vague I., Tregouet D.A. |
| |
|
PAI-1 IN PLATELETS IS DEPENDENT ON THE 4G/5G POLYMORPHISM
|
| Chan D., Wright J.R., Chong N., Goodall A.H. |
| |
|
PAR1 AGONISTS ACCELERATE ULCER HEALING IN RATS
|
| Rusanova A.V., Makarova A.M., Vasilieva T.V., Strukova S.M., Bespalova Z.D. |
| |
|
PAR-1 AND PAR-2 ACTIVATION MEDIATES TISSUE FACTOR INDUCTION IN ENDOTHELIAL CELLS THROUGH A REDOX-SENSITIVE SIGNALING PATHWAY
|
| Barcella S., Banfi C., Brioschi M., Barbieri S.S., Eligini S., Pignieri A., Biglioli P., Tremoli E., Colli S., Mussoni L. |
| |
|
PAR4 INDUCES FULL PLATELET SPREADING ON A FIBRINOGEN MATRIX: INVOLVEMENT OF ERK2 AND P38 AND CA2+ MOBILIZATION
|
| Mazharian A., Roger S., Berrou E., Adam F., Kauskot A., Nurden P., Jandrot-Perrus M., Bryckaert M. |
| |
|
PARACRINE UP-REGULATION OF MONOCYTE CYCLOOXYGENASE-2 BY PLATELETS: ROLE OF TGF-BETA1
|
| Colli S., Eligini S., Barbieri S.S., Arenaz I., Tremoli E. |
| |
|
PARATOPE AND EPITOPE MAPPING OF THE ANTITHROMBOTIC ANTIBODY 6B4 IN COMPLEX WITH PLATELET GLYCOPROTEIN IBALPHA
|
| Fontayne A., De Maeyer B., De Maeyer M., Yamashita M., Matsushita T., Deckmyn H., Deckmyn H. |
| |
|
PARTIAL FIBRIN ADHESION AND DIFFUSION SUGGESTED RETEPLASE AS THE THERAPEUTIC CHOICE FOR CATHETER DRIVEN THROMBOLYSIS
|
| Marcos-Contreras O.A., Ganguly K., Cines D.B., Muzykantov V.R., Murciano J.-C. |
| |
|
PAST AND FUTURE OF GENETIC RESEARCH IN THROMBOSIS
|
| Reitsma P.H., Rosendaal F.R. |
| |
|
PATHOGEN BURDEN AND CORONARY ARTERY DISEASE
|
| Rao V.S., Renuka K.S., Natesha B.K., Shanker J., Mukherjee M., Kakkar V.V. |
| |
|
PATHOGENETIC PROPHYLAXIS OF RECCURENT FETAL LOSS SYNDROME IN PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME AND GENETIC THROMBOPHILIA
|
| Makatsariya A.D., Baimuradova S.M., Bitsadze V.O., Donina E.V., Akinshina S.V. |
| |
|
PATHOPHYSIOLOGICAL MECHANISMS OF VASCULOPATHY IN SYSTEMIC SCLERODERMA (SSC): PLATELET ACTIVATION INDUCED BY APL IS ASSOCIATED WITH ARTERIAL THROMBOSES AND DIGITAL PITTING SCAR IN SSC PATIENTS
|
| Yamazaki M., Kadohira Y., Maekawa M., Arahara M., Ontachi Y., Morishira E., Asakura H., Nakao S. |
| |
|
PATIENTS WITH LUPUS ANTICOAGULANTS AND HISTORY OF THROMBOSIS CARRY ANTIBODIES TO BETA2-GLYCOPROTEIN I INHIBITING THE PHOSPHOLIPID OXIDATION-DEPENDENT ACTIVITY OF APC
|
| Hu Y., Della Valle P., Safa O., Kobzdej M.M., Esmon C.T., D'Angelo A., Esmon N.L. |
| |
|
PATIENTS WITH METABOLIC SYNDROME DEMONSTRATE HIGH PLATELET REACTIVITY AND INCREASED PROCOAGULANT MARKERS
|
| Gurbel P.A., Fattohy S., Singla A., DiChiara J., Bliden K.P., Tantry U.S. |
| |
|
PATIENTS WITH PRIMARY ANTIPHOSPHOLIPID ANTIBODY SYNDROME PRESENT A NORMAL ENDOTHELIAL FUNCTION
|
| Gresele P., Migliacci R., Vedovati C., Becattini C., Guglielmini G., Mezzasoma A., Pegoraro C., Ruffatti A., Pengo V. |
| |
|
PATTERN OF FACTOR VIII INHIBITOR IN PATIENTS WITH HEMOPHILIA A
|
| Modaresi A., Mansouri Torghabe H. |
| |
|
PDI CHAPERONE FUNCTION ENHANCES TF PROCOAGULANT ACTIVITY
|
| Versteeg H.H., Ruf W. |
| |
|
PEDIATRIC DOSING OF AND EXPERIENCE WITH FONDAPARINUX IN DEEP VENOUS THROMBOSIS
|
| Grabowski E.F., Van Cott E. |
| |
|
PEGYLATION PROTECTS FACTOR VIII FROM THE INHIBITION OF ANTIBODY INHIBITORS
|
| Tang L., Pan C., Atwal H., Nixon J., Barnett T., Murphy J.E., Mei B., Fournel M. |
| |
|
PEPTIDE MECHANISMS REGULATION OF HEMOSTASIS IN PURULENT SURGICAL INFECTION
|
| Likhanov I.D., Tsibikov M.N. |
| |
|
PERCUTANEOUS CATHETER EXTRACTION OF A RUPTURED PORT-A-CATH IN A SMALL CHILD WITH HAEMOPHILIA A AND F VIII INHIBITOR USING CONTINUOUS INFUSION OF RFVIIA
|
| Lischetzki G., Topf H., Rauh M., Koch A. |
| |
|
PERFORMANCE AND UTILITY OF A COST-EFFECTIVE COLLAGEN BINDING ASSAY USING TYPE III COLLAGEN
|
| Meiring M.S., Badenhorst P.N. |
| |
|
PERFORMANCE EVALUATION OF THE COAGUCHEK XS SYSTEM IN ROUTINE PATIENT ANTICOAGULATION MANAGEMENT CLINICS IN ISRAEL
|
| Dickstein Y., Waitman D.D.A., van den Besselaar T.A.M. |
| |
|
PERFORMANCE OF A NEW TURBIDIMETRIC D-DIMER ASSAY ADAPTED TO AUTOMATED COAGULOMETERS
|
| Arza B., Sanchez T., Sales M. |
| |
|
PERFORMANCE OF BETHESDA ASSAY AND NIJMEGEN VARIANT IN EXTERNAL QUALITY ASSESSMENT (ECAT) OF FACTOR VIII INHIBITOR ASSAYS
|
| Verbruggen B., Meijer P. |
| |
|
PERFORMANCE OF THE COAGUCHEK XS PLUS SYSTEM USING LIQUID QUALITY CONTROL SAMPLES
|
| Plesch W.J., Wolf T., Dikkeschei B. |
| |
|
PERFORMANCES OF A NEW ELISA (ZYMUTEST HIA) FOR THE DIAGNOSIS OF HEPARIN-INDUCED THROMBOCYTOPENIA
|
| Pouplard C., Rouvier E., Regina S., Gruel Y. |
| |
|
PERINATAL ISCHEMIC STROKE AND THE INCIDENCE OF MATERNAL AND NEONATAL THROMBOPHILIA
|
| Simchen M.J., Goldstein G., Lubetsky A., Tamarin I., Dulitzki M., Schiff E., Kenet G. |
| |
|
PERIODICAL LABORATORY EVALUATION OF PORTABLE COAGULOMETERS
|
| Barcellona D., Fenu L., Cornacchini S., Marongiu F. |
| |
|
PERIOPERATIVE BRIDGING THERAPY WITH LOW MOLECULAR WEIGH HEPARIN IN PATIENTS REQUIRING INTERRUPTION OF LONG-TERM ORAL ANTICOAGULANT THERAPY
|
| Malato A., Cigna V., Saccullo G., Abbene I., Anastasio R., Lo Coco L., Siragusa S. |
| |
|
PERIOPERATIVE PROPHYLACTIC DOSING OF TINZAPARIN IN MORBID OBESE PATIENTS
|
| Attema M.E., Huiberts A.A.M., de Wit L.T., Leyte A., van der Linden C.T.M., Franssen E.J.F. |
| |
|
PEROXIREDOXIN, PRDX1 PLAYS AN IMPORTANT ROLE IN INFLAMMATION AND EARLY ATHEROSCLEROSIS
|
| Kisucka J., Chauhan A.K., Patten I.S., Neumann C., Van Etten R.A., Wagner D.D. |
| |
|
PERSISTENT PLATELET ACTIVATION IN PATIENTS WITH TYPE 2 DIABETES TREATED WITH LOW DOSES OF ASPIRIN
|
| Evangelista V., De Berardis G., Totani L., Dell'Elba G., Amore C., Manarini S., Pecce R., Maione A., Tognoni G., Nicolucci A. |
| |
|
PERSISTENT PLATELET MICROPARTICLE FORMATION IN THE PRESENCE OF BLOCKERS OF GP IBALPHA, GPIIB/IIIA, CALCIUM CHELATORS AND ADP SCAVENGERS UNDER HIGH SHEAR STRESS
|
| Forestier M., Reséndiz J.C., Lassila R., Büchi L., Beer J.H. |
| |
|
PERSISTENT TXA2 PRODUCTION IN PATIENTS CHRONICALLY TREATED WITH ASPIRIN: RESIDUAL COX-1 ACTIVITY OR COX-2 ACTIVATION?
|
| Pulcinelli F.M., Principessa L., Trifirò E., Di Renzo L., Cacciavillani S., Riondino S. |
| |
|
PERSISTENT VENOUS SYMPTOMS AND SIGNS 1 MONTH AFTER A FIRST DIAGNOSIS OF DVT PREDICT DEVELOPMENT OF THE POST-THROMBOTIC SYNDROME (PTS) DURING 2 YEARS FOLLOW-UP
|
| Kahn S.R., Ducruet T., Shrier I., Miron M., Roussin A., Desmarais S., Joyal F., Kassis J., Solymoss S., Desjardins L., Ginsberg J. |
| |
|
PHARMACO-ECONOMIC EVALUATION OF TREATMENT ALTERNATIVES FOR MILD TO MODERATE BLEEDING EPISODES IN PATIENTS WITH HAEMOPHILIA WITH INHIBITORS IN KOREA
|
| Yoo S.K., Yong L.S., Kyu P.S., Woo Y.C. |
| |
|
PHARMACOGENETICS OF ORAL ANTICOAGULATION - VKORC1-HAPLOTYPES DETERMINE THE INTER-INDIVIDUAL VARIABILITY
|
| Geisen C., Luxembourg B., Sittinger K., Toennes S.W., Watzka M., Lindhoff-Last E., Seifried E., Oldenburg J. |
| |
|
PHARMACOKINETIC PROFILES AND PHARMACOKINETIC AND PHARMACODYNAMIC RELATIONSHIP OF A VWF INHIBITORY APTAMER IN THE CYNOMOLGUS MONKEY
|
| Hutabarat R.M., McCauley T., Makim A., Lewis S., Merlino P., Gilbert M., Bouchard P. |
| |
|
PHARMACOKINETIC/PHARMACODYNAMIC PROFILE OF A NOVEL APTAMER DIRECT THROMBIN INHIBITOR IN CYNOMOLGUS MONKEYS AND YORKSHIRE PIGS FOLLOWING A SINGLE IV BOLUS ADMINISTRATION
|
| Hutabarat R.M., McCauley T., Makim A., Lewis S., Olsen K., Wagner-Whyte J., Diener J., Matyugicheva U., Scull J., Levy M.D., Deitcher S.D., Funk W.D., Bouchard P. |
| |
|
PHARMACOKINETICS (PK) AND PHARMACODYNAMICS (PD) OF RIVAROXABAN: A COMPARISON OF ONCE- AND TWICE-DAILY DOSING IN PATIENTS UNDERGOING TOTAL HIP REPLACEMENT (THR)
|
| Eriksson B.I., Misselwitz F., Mueck W. |
| |
|
PHARMACOKINETICS (PK) OF RVWF IN DOGS AND MICE WITH SEVERE VWD
|
| Nichols T.C., Merricks E., Muchitsch E.M., Baumgartner B., Turecek P.L., Ahmad R.U., Gritsch H., Schwarz H.P. |
| |
|
PHARMACOKINETICS (PK) OF SUBCUTANEOUS FONDAPARINUX 1.5 MG IN PATIENTS WITH MODERATE RENAL IMPAIRMENT (MRI)
|
| Boyle D., Turpie A.G. |
| |
|
PHARMACOKINETICS AND DOSE-FINDING OF FRAGMIN IN PEDIATRIC PATIENTS AT RISK FOR THROMBOEMBOLIC EVENTS
|
| Mitchell L.G., Barrett J., Cox P., Vegh P., Patel D., Castillo M., Massicotte P. |
| |
|
PHARMACOKINETICS AND PHARMACODYNAMICS OF DABIGATRAN ETEXILATE IN SUBJECTS WITH MODERATE HEPATIC IMPAIRMENT
|
| Stangier J., Rathgen K., Stähle H., Shakeri-Nejad K. |
| |
|
Pharmacokinetics of a mixture of FVIIa and FX in rats
|
| Nakatomi Y., Matsui H., Tsuji M., Shiranita A., Nakamura T., Nakashima T., Gokudan S., Miyazaki H., Oonishi S., Kusumoto E., Tomokiyo K., Ogata Y., Shigaki T. |
| |
|
PHARMACOKINETICS OF A PROTHROMBIN COMPLEX CONCENTRATE IN HEALTHY VOLUNTEERS
|
| Ostermann H., Knaub S. |
| |
|
PHARMACOKINETICS OF DALTEPARIN IN PROPHYLACTIC DOSAGE IN PATIENTS WITH IMPAIRED RENAL FUNCTION
|
| Schmid P., Brodmann D., Fischer A.G., Wuillemin W.A. |
| |
|
PHARMACOKINETICS OF DIPETARUDIN AND PEG-DIPETARUDIN IN PIGS
|
| Lopez M., Koehler A., Nowak G. |
| |
|
PHARMACOKINETICS OF THE REFORMULATED B-DOMAIN DELETED RECOMBINANT FACTOR VIII (BDD-RFVIII) CONCENTRATE USING CHROMOGENIC AND ONE-STAGE ASSAYS WITH POOLED NORMAL PLASMA (PNP) AND REFACTO LABORATORY STANDARD (RLS)
|
| Santoro C., Iorio A., Pignoloni P., Rago A., Biondo F., Ferrante F., Agnelli G., Mazzucconi M. |
| |
|
PHARMACOLOGICAL CHARACTERIZATION OF AN ORAL DIRECT THROMBIN INHIBITOR, MCC-977: HIGH THROMBIN SPECIFICITY AND LOW HEMORRHAGIC PROFILE
|
| Nakajima M., Suga M., Sugawara K., Katsu M., Yuki S., Anabuki J., Yamamoto T., Abe Y., Kitada Y. |
| |
|
PHARMACOLOGICAL TARGETING OF PLATELETS BY ORALLY ACTIVE PI3-KINASE B INHIBITOR PROTECTS AGAINST ARTERIAL THROMBOSIS
|
| Tchernychev B., Jussif J., Warren M., Fazo N., Feng G., Sushkova N., Smith T.M., Bridson G., Xu X., Wang Q., Carter L. |
| |
|
PHASE 3 STUDY COMPARING RECOMBINANT HUMAN THROMBIN AND BOVINE THROMBIN FOR SURGICAL HEMOSTASIS
|
| Renkens K., Chapman W., Weaver F., Murphy A., Reynolds T.C., Pribble J. |
| |
|
PHENOMENON OF THE STRENGTHENING OF THE CLOT AFTER ITS STRETCHING DESTRUCTION: NONTHROMBOCYTE PLASMA
|
| Savushkin A.V. |
| |
|
PHENOTYPE AND FUNCTION OF CD4+CD25+ REGULATORY T CELLS IN MOUSE MODEL OF EXPERIMENTAL TRANSIENT IMMUNE THROMBOCYTOPENIA AFTER TREATMENT WITH INDIRUBIN
|
| Zhang A.J., Zhao Y., Zhang B.J., Ji X.B., Wang L., Peng J., Hou M. |
| |
|
PHENOTYPE HETEROGENEITY IN SEVERE HAEMOPHILIA
|
| van den Berg H.M., de Groot P.G., Fischer K. |
| |
|
PHENOTYPIC ANALYSIS OF THREE MUTATIONS CAUSING GLANZMANN THROMBASTHENIA
|
| Artoni A., Gelain F., Afrasiabi A., De Mattio M., Margaglione M., Mannucci P.M. |
| |
|
PHORBOL 12-MYRISTATE 13-ACETATE (PMA) RESPONSIVE SEQUENCE IN G ALPHA Q PROMOTER DURING MEGAKAYOCYTIC DIFFERENTIATION: REGULATION BY EGR-1
|
| Jalagadugula G.S., Dhanasekaran D., Koneti Rao A. |
| |
|
PHOSPHODIESTERASE-TYPE IV REGULATES PMN/PLATELET INTERACTION IN VITRO AND PMN ACCUMULATION AT THE SITE OF VASCULAR INJURY IN VIVO
|
| Totani L., Pamuklar Z., Manarini S., Piccoli A., Federico L., Pecce R., Martelli N., Evangelista V., Smyth S.S. |
| |
|
PHOSPHOINOSITIDE 3-KINASE-INDUCED CYTOSKELETAL TRANSLOCATION OF PROTEIN KINASE CK2 IN THROMBIN-STIMULATED PLATELETS
|
| Nakanishi K., Ido M., Tanaka S., Bonno M., Yamamoto H., Komada Y., Gabazza E.C., Hayashi T., Suzuki K. |
| |
|
PHOSPHOLIPID REGULATION OF COAGULATION REACTIONS
|
| Hathcock J.J., Nemerson Y. |
| |
|
PHOSPHOPROTEIN PROFILING OF COLLAGEN PEPTIDE ACTIVATED PLATELETS: A FOCUS ON SERINE AND THREONINE PHOSPHORYLATION EVENTS
|
| Howes J.M., Lilley K.S., Farndale R.W. |
| |
|
PHYSICAL ACTIVITY AND CARDIOVASCULAR RISK FACTORS IN A MIDDLE-AGED URBAN ITALIAN POPULATION
|
| Sofi F., Capalbo A., Cesari F., Marcucci R., Gori A., Fedi S., Casini A., Surrenti C., Abbate R., Gensini G. |
| |
|
PHYSICAL ACTIVITY DURING LEISURE TIME AND PRIMARY PREVENTION OF CORONARY HEART DISEASE: AN UPDATED METAANALYSIS OF COHORT STUDIES
|
| Sofi F., Capalbo A., Cesari F., Pucci N., Fatini C., Macchi C., Califano S., Gensini F., Abbate R., Gensini G. |
| |
|
PHYSICAL EXAMINATION IN PATIENTS WITH SEVERE HEMOPHILIA UNDER PROPHYLACTIC TREATMENT - EFFICACY OF AN EARLY LONG-TERM PROPHYLAXIS?
|
| Masurat S., Weidenhammer A., Christensen K., Spranger T., Takla A., Auerswald G. |
| |
|
PHYTOESTROGENS DOWN-REGULATE PROTEIN S EXPRESSION IN HEPG2 CELLS
|
| Tsuda H., Tadokoro K., Hiroto Y., Kishikawa M., Nakazono E. |
| |
|
PLAQUE PROGRESSION AND REGRESSION IN ATHEROTHROMBOSIS
|
| Ibanez B., Vilahur G., Badimon J.J. |
| |
|
PLASMA ANGIOGENIC ACTIVITY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOUS
|
| Sakly N., Mirshahi P., Soria J., Ghedira I., Mirshahi M. |
| |
|
PLASMA COAGULATION TESTS AND GENETIC THROMBOPHILIC MUTATION STUDIES ARE MANDATORY FOR PREVENTING THE IDIOPATHIC RECURRENT ABORTIONS OR REPEATED FETAL LOSS IN HEALTHY WOMEN
|
| Musso R., Nardo F., Cultrera D., Sortino G., Azzaro M., Cipolla A., Di Francesco E., Musso M., Musso A. |
| |
|
PLASMA CONCENTRATIONS OF TISSUE FACTOR AND COAGULATION FACTOR XIIA IN PREGNANT WOMEN
|
| Wolf H.H., Frühauf A., Schmoll H.J. |
| |
|
PLASMA D-DIMER CORRELATES WITH AGE, CAROTID ARTERIAL OR THORACIC AORTIC ATHEROSCLEROSIS
|
| Hanzawa K., Okamoto T., Sato K., Hayashi J. |
| |
|
PLASMA EXCHANGE AND ASPIRIN PLUS HIGH VERSUS STANDARD DOSE STEROIDS IN IDIOPATHIC THROMBOCYTOPENIC PURPURA (TTP): A PROSPECTIVE, RANDOMIZED STUDY BY THE ITALIAN GROUP FOR PTT
|
| Balduini C.L., Luppi M., Laurenti L., Klersy C., Pieresca C., Quintini G., Iuliano F., Centurioni R., Spedini P., Vianelli N., Zaccaria A., Pogliani E., Musso R., Bobbio Pallavicini E., Quarta G., Galieni P., Fragasso A., Casella L., Gugliotta L. |
| |
|
PLASMA FIBRINOLYTIC POTENTIAL AND THE RISK OF VENOUS THROMBOEMBOLISM (VTE) RECURRENCE
|
| Colucci M., Binetti B.M., Semeraro N., Legnani C., Cosmi B., Palareti G. |
| |
|
PLASMA INCOAGULABILITY INDUCED BY LONOMIA OBLIQUA BRISTLE EXTRACT IS ASSOCIATED WITH THE ABUNDANT PRESENCE OF LIPOCALINS
|
| Ricci-Silva M., Carrijo Carvalho C.L.C., Zannin Z.M., Silverio S.A., Valente V.R.H., Leon L.I.R., Perales P.J., Tambourgi T.D.V., Morais M.J.F., Chudzinski Tavassi A.M. |
| |
|
PLASMA LEVEL OF STROMAL DERIVED FACTOR-1 (SDF-1) IS INCREASED IN DISSEMINATED INTRAVASCULAR COAGULATION PATIENTS WHO HAVE A POOR OUTCOME: IN VITRO EFFECT OF SDF-1 ON COAGULOPATHY
|
| Kim H., Kim J., Chung J., Han K., Park S., Cho H. |
| |
|
PLASMA LEVELS OF CLOTTING FACTORS ARE POSITIVELY CORRELATED IN HEALTHY POPULATION: A COMPREHENSIVE PERSPECTIVE TO ASSESS THROMBOTIC RISK?
|
| Mezzano D., Panes O., Matus V., Muñoz B., Goycoolea M., Pereira J., Quiroga T. |
| |
|
PLASMA LEVELS OF COAGULATION AND INFLAMMATORY MARKERS IN SUBJECTS AFFECTED WITH CORONARY ARTERY DISEASE
|
| Rao V., Natesha B.K., Kanjilal S., Mukherjee M., Kakkar V.V. |
| |
|
PLASMA LEVELS OF HOMOCYSTEINE (HCY) AND OTHER PARAMETERS INTERRELATED IN PATIENTS WITH PERIPHERAL ARTERIAL OBSTRUCTIVE DISEASE (PAOD)
|
| Mota A.P.L., Santos M.E.R.C., Fernandes A.P.S.M., Silva F.C.L., Carvalho M.G. |
| |
|
PLASMA LEVELS OF PROTHROMBIN FRAGMENT F1+2, D-DIMER, AND PROTHROMBIN TIME IN GASTRIC CANCER PATIENTS CORRELATE WITH CLINICAL STAGE AND LYMPH NODE METASTASIS
|
| Han J., Koh R., Lee S., Kim S., Oh S., Kim S., Kim M., Kim H., Kwon H. |
| |
|
PLASMA PROCPU (TAFI) AND CLOT LYSIS TIME ARE CORRELATED WITH CLOTTING FACTOR LEVELS AND THROMBIN GENERATION: A NOVEL APPROACH TO ASSESS THROMBOSIS RISK?
|
| Quiroga T., Willemse J.L., Matus V., Munoz B., Panes O., Goycoolea M., Pereira J., Hendriks D., Mezzano D. |
| |
|
PLASMA PROTEOMICS IN HEMOPHILIA A PATIENTS AFTER FVIII ADMINISTRATION
|
| van Geffen M.H.A., Verbruggen B., van Kraaij M.G.J., Novakova I.R.O., van Heerde W.L. |
| |
|
PLASMA S/R RATIO OF WARFARIN CO-VARIES WITH VKORC1 HAPLOTYPE
|
| Osman M., Enström C., Lindahl T. |
| |
|
PLASMA THROMBOMODULIN IN PRE-ECLAMPSIA
|
| Dusse L.M.S., Carvalho M.G., Cooper A.J., Lwaleed B.A. |
| |
|
PLASMA-DERIVED VERSUS RECOMBINANT PRODUCTS FOR HAEMOPHILIA TREATMENT ?
|
| Goudemand J., Calvez T. |
| |
|
PLASMAFHERESIS (PA) INFLUENCE ON MORPHOLOGICAL STATUS OF PLATELES (PLT) AT WOMEN WITH SPONTANEOS ABORTIONS - INFLAMMATORY GENESIS
|
| Ochan A.S., Strelnicova E.V. |
| |
|
PLASMIN INDUCES PROINFLAMMATORY STIMULATION OF HUMAN MACROPHAGES VIA THE ANNEXIN A2 HETEROTETRAMER
|
| Laumonnier Y., Li Q., Syrovets T., Simmet T. |
| |
|
PLASMIN SYSTEM REGULATION IN OVA-SENSITIZED RAT MODEL OF ASTHMA
|
| Kucharewicz I., Mogielnicki A., Tankiewicz-Kwedlo A., Bodzenta-Lukaszyk A., Buczko W. |
| |
|
PLASMINOGEN ACTIVATOR INHIBITOR -1 (PAI-1) PLASMA LEVELS AND 4G/5G AND G844A PAI-1 PROMOTER POLYMORFISMS IN BRAZILIAN PATIENTS WITH ISQUEMIC STROKE AND PERIPHERAL ARTERIAL DISEASE
|
| Sabino A.P., Carvalho M.G., Ribeiro D.D., Lima L.M., Domingheti C.P., Paiva S.G., Dusse L.M.S., Fernandes A.P.S.M. |
| |
|
PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) 4G/4G GENOTYPE MAY INCREASE THE RISK OF THROMBOSIS IN SUBSET OF PATIENTS WITH PROTHROMBIN G20210A GENE MUTATION
|
| Bykowska K., Vertun-Baranowska B., Stefanska E., Windyga J., Podolak-Dawidziak M. |
| |
|
PLASMINOGEN ACTIVATOR INHIBITOR-1 4G/5G POLYMORPHISM IN CORONARY ARTERY DISEASE AND ITS ASSOCIATION WITH PLASMA PAI-1 LEVELS
|
| Lima L.M., Sousa M.O., Neto C.P.F., Garcia J.C.F., Fernandes A.P., Dusse L.M.S., Carvalho M.G. |
| |
|
PLASMINOGEN ACTIVATOR INHIBITOR-1 ACTIVITY PREDICTS RHYTHM OUTCOME AFTER ELECTRICAL CARDIOVERSION FOR ATRIAL FIBRILLATION
|
| Tveit A., Seljeflot I., Grundvold I., Abdelnoor M., Smith P., Arnesen H. |
| |
|
PLASMINOGEN ACTIVATORS IN EXPERIMENTAL IMMUNE NEPHRITIS
|
| Podorolskaya L.V. |
| |
|
PLASSMINOGEN ACTIVATORS AND PROTEASES IN ISCHEMIC STROKE
|
| del Zoppo G.J. |
| |
|
PLATELET ABNORMALITIES IN PATIENTS WITH CONSTITUTIONAL DEFECTS IN FILAMIN A
|
| Nurden P., Nurden A.T., Solé G., Combrié R., Lacombe D., Arveiler B., Goizet C. |
| |
|
PLATELET ACTIVATION AND MYOCARDIAL ISCHEMIC EVENTS IN PATIENTS UNDERGOING MAJOR VASCULAR SURGERY
|
| Rajagopalan S., Ford I., Bachoo P., Hillis G., Croal B., Greaves M., Brittenden J. |
| |
|
PLATELET ACTIVATION INCREASES WITH THE SEVERITY OF PERIPHERAL ARTERIAL DISEASE: IMPLICATIONS FOR CLINICAL MANAGEMENT
|
| Mckay I., Rajagopalan S., Ford I., Bachoo P., Greaves M., Brittenden J. |
| |
|
PLATELET ACTIVATION REINFORCES THE PROCOAGULANT PHENOTYPE INDUCED BY MURINE MONOCLONAL ANTI-PHOSPHOLIPID ANTIBODIES
|
| Membre A., Wahl D., Max J.P., Lacolley P., Lecompte T., Regnault V. |
| |
|
PLATELET ACTIVATION RESPONSE IS MORE SENSITIVE TO THROMBIN STIMULATION THAN IS PLATELET APOPTOSIS
|
| Leytin V., Allen D.J., Lyubimov E., Freedman J. |
| |
|
PLATELET ACTIVATION TRIGGERS ACTIVATION OF THE TISSUE FACTOR REGULATOR, PROTEIN DISULPHIDE ISOMERASE
|
| Chen V.M., Hotchkiss K.A., Hogg P.J. |
| |
|
PLATELET ACTIVATION VIA THROMBIN RECEPTOR PAR4 IS INVOLVED IN THE INITIATION OF THROMBIN GENERATION AND COAGULATION AND IN CLOT ELASTICITY DEVELOPMENT
|
| Ramström S., Vretenbrant Öberg K., Bjerke M., Lindahl T.L. |
| |
|
PLATELET ADAMTS13 AND IN VITRO EXPRESSION STUDY OF A PATIENT AFFECTED BY CONGENITAL TTP
|
| Lavoretano S., Lombardi R., Garagiola I., Palla R., Afrasiabi A., Mannucci P.M., Peyvandi F. |
| |
|
PLATELET ADHESION STUDIES ON NANOSTRUCTURED POLY (LACTIC-CO-GLYCOLIC ACID) CARBON NANOTUBE COMPOSITE
|
| Koh L.B., Zhou J.J., Rodriguez I. |
| |
|
PLATELET ADHESION TO LAMININ IS MEDIATED THROUGH VON WILLEBRAND FACTOR AND GLYCOPROTEIN IB UNDER HIGH SHEAR FLOW
|
| Inoue O., Suzuki-Inoue K., Satoh K., Ozaki Y. |
| |
|
PLATELET AGGREGATION AND SEROTONIN ACTIVITY
|
| Berger J.S., Becker R.C., Ortel T.L., Kuhn C.M., Helms M.J., Williams R.B. |
| |
|
PLATELET AGGREGATION INHIBITING COMPONENTS FROM VIPERA LEBETINA SNAKE VENOM
|
| Siigur E., Samel M., Tonismagi K., Vija H., Trummal K., Aaspollu A., Pikver R., Subbi J., Siigur J. |
| |
|
PLATELET AGGREGATION IS ENHANCED UNDER CONDITIONS OF HYPOTHERMIA
|
| Xavier R., White A., Fox S., Heptinstall S. |
| |
|
PLATELET AND MONOCYTE ACTIVATION IN PATIENTS UNDERGOING CIRCULATORY SUPPORT WITH LEFT VENTRICULAR ASSIST DEVICES (LVAD)
|
| Matijevic N., Radovancevic R., Bracey A., Radovancevic B., Gregoric I., Frazier O. |
| |
|
PLATELET ARCHITECTURE IN THREE DIMENSIONS
|
| van Nispen tot Pannerden H., Geerts W.J.C., Heijnen H.F.G. |
| |
|
PLATELET BUT NOT LEUKOCYTE ACTIVATION IS A PREREQUISITE FOR PLATELET-LEUKOCYTE INTERACTION IN HUMAN WHOLE BLOOD
|
| Izzi B., Pampuch A., de Gaetano G., Cerletti C. |
| |
|
PLATELET CHEMOTAXIS INDUCED BY THE SDF-1/CXCR4 CHEMOKINE RECEPTOR SYSTEM
|
| Boukour S., Capron C., Cramer-Borde E. |
| |
|
PLATELET DELAY TIME AS MEASURED IN THE ARTERIOLES OF RATS USING LASER INDUCED THROMBOSIS
|
| Kratzer M.A.A., Yamashita T., Yamamoto J. |
| |
|
PLATELET DENSE GRANULE SECRETION ACCELERATES THE DEVELOPMENT OF ARTERIOSCLEROSIS AFTER VASCULAR INJURY
|
| King S.M., McNamee R.A., Patel R., Mehta H., Brands M., Reed G.L. |
| |
|
PLATELET DEPOSITION IN RABBIT COMMON CAROTID ARTERIES PROMOTED BY ARTERIAL STENOSIS AND SPASM
|
| Jørgensen L., Straume B.K., Mustard J.F. |
| |
|
PLATELET EP3 RECEPTORS AS TARGETS FOR ANTITHROMBOTIC AGENTS - COMPARISON OF DG-041 WITH ASPIRIN AND AR-C69931
|
| Manolopoulos P., Iyu Espinosa D., Anders B., Gurney M., Hermann D., Hartman D., Heptinstall S. |
| |
|
PLATELET FACTOR 4 (PF4/CXCL4) SEALS BLOOD CLOTS BY ALTERING THE STRUCTURE OF FIBRIN
|
| Amelot A.A., Tagzirt M., Ducouret G., Lai Kuen R., Le Bonniec B.F. |
| |
|
PLATELET FACTOR 4 EXERTS A NEGATIVE PARACRINE EFFECT ON MEGAKARYOPOIESIS THROUGH LIPOPROTEIN RELATED PROTEIN RECEPTOR-1 ON MEGAKARYOCYTIC PRECURSORS
|
| Lambert M.P., Wang Y., Kowalska M., Poncz M. |
| |
|
PLATELET FACTOR V DEFICIENCY IN A PATIENT WITH AN ACQUIRED INHIBITOR OF VA PROCOAGULANT FUNCTION
|
| Jeimy S.B., Krakow E.F., Fuller N., Tasneem S., Crowther M., Hayward C.P.M. |
| |
|
PLATELET FUNCTION (PFA-100) AND ACTIVATION IN PATIENTS WITH CHRONIC PHILADELPHIA NEGATIVE MYELOPROLIFERATIVE DISORDERS: ROLE OF THE JAK2 V617F MUTATION
|
| Moreno M.J., Martínez C., Navarro-Núñez L., Ferrer F., Vicente V., Lozano M.L., González M.H., Rivera J. |
| |
|
PLATELET FUNCTION EVALUATION BY USING A NEW POINT-OF-CARE SYSTEM AND PLATELET LIGHT-TRANSMISSION AGGREGATION IN A LARGE COHORT OF CORONARY ARTERY DISEASE PATIENTS
|
| Panicca R., Antonucci E., Romano E., Gori A., Marcucci R., Attanasio M., Poli S., Prisco D., Abbate R., Gensini G. |
| |
|
PLATELET FUNCTION IN IMMUNE THROMBOCYTOPENIA (M. WERLHOF)
|
| Scholz U., Siegemund A. |
| |
|
PLATELET FUNCTION MEASURED BY VERIFYNOW IDENTIFIES GENERALIZED HIGH PLATELET REACTIVITY IN ASPIRIN TREATED PATIENTS
|
| DiChiara J., Bliden K.P., Tantry U.S., Kreutz R.P., Chaganti S.K., Gesheff T.B., Kreutz Y., Gurbel P.A. |
| |
|
PLATELET FUNCTION TESTING IN CHILDREN UNDER 1 YEAR
|
| Mathias M.C., Khair K., Burgess C., Liesner R. |
| |
|
PLATELET FUNCTION THROMBOELASTOGRAPHY (PFT)
|
| Pluthero F.G., Rand M.L., Brandao L.R., Blanchette V.S., Kahr W.H. |
| |
|
PLATELET FUNCTION UNDER HIGH SHEAR CONDITION CORRELATES WITH CLINICAL ESTIMATION OF HEMORRHAGE IN CHRONIC AUTOIMMUNE THROMBOCYTOPENIA
|
| Panzer S., Rieger M., Vormittag R., Eichelberger B., Dunkler D., Pabinger I. |
| |
|
PLATELET GENOMICS AND THE RISK OF ARTHEROTHROMBOSIS
|
| Ouwehand W.H. |
| |
|
PLATELET GLYCOPROTEINS: PREDICTORS OR PROGRESSION MARKERS IN CARDIOVASCULAR DISEASE?
|
| Gurney D.A., Moore G.W., Rangarajan S. |
| |
|
PLATELET GPIIBIIIA-FIBRINOGEN BINDING ACTIVITY IS INCREASED BY ALLICIN (A THIOL-REACTIVE REAGENT)
|
| Manaster Y., Shenkman B., Mor-Cohen R., Rosenberg N., Savion N. |
| |
|
PLATELET INFUSION IMPROVED THE HAEMOSTATIC EFFECT OF RECOMBINANT FACTOR VIIA IN A PATIENT WITH INHIBITOR HAEMOPHILIA UNDERGOING ELECTIVE KNEE REPLACEMENT: SIGNIFICANCE OF THE RFVIIA GLA-DOMAIN BINDING TO PLATELETS
|
| Sørensen B., Ingerslev J. |
| |
|
PLATELET INTEGRIN ALPHA2BETA1 INTERACTION WITH TYPE I COLLAGEN IS INHIBITED BY A NOVEL SYNTHETIC MOLECULE BTT-3016
|
| Jouppila A., Nissinen L., Pentikäinen O.T., Käpylä J., Ojala M., Lehtisalo J., Johnson M.S., Marjamäki A., Heino J., Lassila R. |
| |
|
PLATELET IS AN IMPORTANT FACTOR IN VENOUS THROMBOEMBOLISM: INTERACTION OF VON WILLEBRAND FACTOR AND PLATELET GPIB PROMOTES VENOUS THROMBUS GROWTH
|
| Takahashi M., Yamashita A., Moriguchi-Goto S., Marutsuka K., Koshimoto C., Asada Y. |
| |
|
PLATELET ITIM PROTEINS INHIBIT BASAL SIGNALLING BY YXXL-CONTAINING PLATELET ACTIVATION RECEPTORS
|
| Mori J., Pearce A.C., Spalton J.C., Tomlinson M.G., Senis Y.A., Watson S.P. |
| |
|
PLATELET MICROPARTICLES ARE A PREDICTIVE FACTOR OF OVERALL SURVIVAL IN PATIENTS WITH PROSTATE CANCER
|
| Helley D., Banu E., Bouziane A., Banu A., Oudard S., Fischer A.M. |
| |
|
PLATELET MICROPARTICLES CONTAIN ACTIVE CASPASE 3
|
| Böing A.N., Hau C.M., Sturk A., Nieuwland R. |
| |
|
PLATELET MICROPARTICLES LEVELS AND PREVALENCE OF ANTIPROTHROMBIN AND ANTI-BETA-2-GLYCOPROTEIN I ANTIBODIES IN THROMBOANGIITIS OBLITERANS (BUERGER'S DISEASE)
|
| Darnige L., Helley D., Smadja D.M., Bura A., Bouziane A., Lewkowicz E., Emmerich J., Fischer A.M., Fiessinger J.N. |
| |
|
PLATELET POLYPHOSPHATE MODULATES PLATELET COAGULATION PROTEIN RESPONSES
|
| Mutch N.J., Smith S.A., Gahl W.A., Simioni P., Morrissey J.H. |
| |
|
PLATELET PROINFLAMMATORY AND HEMOSTATIC FUNCTIONS IN PATIENTS WITH CYSTIC FIBROSIS
|
| Sturm A., Hebestreit H., Koenig C., Speer C.P., Walter U., Grossmann R. |
| |
|
PLATELET PROTEIN DISABLED-2 IS REQUIRED FOR EMBRYONIC STEM CELL-DERIVED MESODERM FORMATION AND MEGAKARYOCYTIC DIFFERENTIATION
|
| Huang C., Cheng J., Tseng C. |
| |
|
PLATELET P-SELECTIN IS ASSOCIATED WITH CIRCULATING NEUTROPHIL ACTIVATION AT THE VERY ONSET OF MYOCARDIAL INFARCTION
|
| Maugeri N., Godino C., Evangelista V., Mussardo M., Figini F., Colombo A., Cianflone D., Manfredi A., Maseri A. |
| |
|
PLATELET RECEPTOR P2Y12 HAPLOTYPES PREDICT RESTENOSIS AFTER PERCUTANEOUS CORONARY INTERVENTIONS
|
| Rudez G., Monraats P.S., Leebeek F.W.G., Schrevel M., Zwinderman A.H., de Winter R.J., Tio R.A., Doevendans P.A.F.M., Jukema J.W., de Maat M.P.M. |
| |
|
PLATELET RECEPTOR RECOGNITION AND CROSSTALK IN COLLAGEN-INDUCED ACTIVATION OF PLATELETS
|
| Farndale R.W., Slatter D.A., Siljander P.R.M., Jarvis G.E. |
| |
|
PLATELET REFRACTORINESS DUE TO ANTI-HLA AND ANTI-HPA-5A ALLOANTIBODIES: CLINICAL MANAGEMENT DURING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
|
| Arber C., Bertrand G., Halter J., Boehlen F., Kaplan C., Gratwohl A. |
| |
|
PLATELET RESPONSE DOES NOT CHANGE DURING LONG-TERM-TREATMENT (8YEARS) WITH 50 OR 100 MG ACETYLSALICYLIC ACID (ASA) FOR SECONDARY PREVENTION
|
| Sinzinger H., Kritz H., Berent R., Schmid P., Steinbrenner D. |
| |
|
PLATELET RESPONSIVENESS TOWARDS ANTIPLATELET MEDICATIONS BEFORE AND AFTER CORONARY ANGIOGRAPHY AND PERCUTENOUS CORONARY INTERVENTIONS AS DETERMINED BY WHOLE BLOOD AGGREGOMETRY
|
| von Pape K.W., Calatzis A., Bonzel T., Conze M., Spannagl M., Weisser H. |
| |
|
PLATELET THROMBUS GROWTH ANGLE (PTGA) VERSUS CLOSURE TIME (CT) IN VON WILLEBRAND PATIENTS TYPE I AS MEASURED WITH THE PLATELET FUNCTION ANALYSER
|
| Kretschmer V., Koy E., Weippert-Kretschmer M., Kratzer M.A.A. |
| |
|
PLATELET TYPE VON WILLEBRAND DISEASE: AN UNDERDIAGNOSED CAUSE OF EXCESSIVE MUCOCUTANEOUS BLEEDING
|
| Othman M., Leggo J., Notley C., James P., Lillicrap D. |
| |
|
PLATELET VOLUME IN CORD BLOOD
|
| Ihara A., Nishiura T., Uchida Y., Abe K., Tanaka F., Matsui K., Shouno S. |
| |
|
PLATELET-BOUND PF4 IS TARGETED BY HIT ANTIBODIES IN THE ABSENCE OF HEPARIN
|
| Prechel M.M., Jeske W.P., Walenga J.M. |
| |
|
PLATELET-DERIVED NITRIC OXIDE CONTRIBUTE TO THE REGULATION OF BLOOD PRESSURE IN MICE
|
| Momi S., Ruggeri L., Cecchetti L., Gresele P. |
| |
|
PLATELET-FACILITATED DELIVERY OF ANGIOGENESIS REGLULATORS IS CONTROLLED BY TISSUE PROTEASES
|
| Klement G.L., Cervi D., Italiano J.E., Bhattacharya N. |
| |
|
PLATELET-LEUKOCYTE INTERACTION: A CLEAR AGE DEPENDENCY
|
| Sturm A., Speer C.P., Grossmann R. |
| |
|
PLATELETS AND BACTERIA
|
| Cox D. |
| |
|
PLATELETS AND INNATE IMMUNITY
|
| Freedman J., Semple J.W. |
| |
|
PLATELETS AND LEUKOCYTE INTERACTION WITH THE VESSEL WALL
|
| Wagner D. |
| |
|
PLATELETS AND SUBENDOTHELIAL MATRIX PROTEINS DIFFERENTIALLY SUPPORT ADHESION OF LYMPHOCYTE SUBPOPULATIONS UNDER ARTERIAL SHEAR STRESS
|
| Spectre G., Ersoy M., Hjemdahl P., Savion N., Varon D., Li N. |
| |
|
PLATELETS AND VIRUSES
|
| Cramer-Borde E.M., Boukour S., Flaujac C. |
| |
|
PLATELETS INDUCE PAI-1 GENE EXPRESSION IN MONOCYTES THROUGH TGF-BETA
|
| Chan D., Wright J.R., Codd V., Chong N., Goodall A.H. |
| |
|
PLATELETS RECRUIT BONE MARROW-DERIVED PROGENITOR CELLS TO ARTERIAL THROMBI IN VIVO
|
| Schulz C., Konrad I., Schürzinger K., von Brühl M.L., Lorenz M., Schneider S., Schiemann M., Rudelius M., Frampton J., Gawaz M., Massberg S. |
| |
|
PLATELETS, INFLAMMATION AND ATHEROSCLEROSIS
|
| Lindenmann S., Krämer B., Seizer P., Gawaz M. |
| |
|
POINT OF CARE INR MONITORING IN CHILDREN WITH VENTRICULAR ASSIST DEVICES
|
| Bauman M.E., Conway J., Buchholz H., Mitchell L., Rebeyka I., Massicotte M. |
| |
|
POINT-OF-CARE ASSESSMENT OF PERI-OPERATIVE PLATELET FUNCTION USING THROMBOELASTOGRAPH PLATELET MAPPING
|
| Melikian C.N., Mallett S.V. |
| |
|
POISONING WITH SUPERWARFARIN
|
| Jones L.A., Sánchez-Luceros A., Meschengieser S.S., Casais P., Grosso S., Blanco A.N., Shearer M., Lazzari M.A. |
| |
|
POLYCYTHAEMIA VERA, ANTIPHOSPHOLPID ANTIBODIES AND ACQUIRED PLATELET FUNCTION ABNORMALITIES
|
| Toth J., Muszbek L., Kappelmayer J., Szanto T., Szarvas M., Rejto L., Soltesz P., Udvardy M., Harsfalvi J. |
| |
|
POLYMORPHIC AND MUTAGENIC SEQUENCE CHANGES IN THE A1 AND A2 DOMAINS OF VON WILLEBRAND FACTOR (VWF) RESULT IN ALTERATIONS TO ADAMTS13 CLEAVAGE EFFICIENCY
|
| Pruss C.M., Notley C.R.P., Hegadorn C.A., O'Brien L.A., Lillicrap D.P. |
| |
|
POLYMORPHISMS IN COAGULANT AND INFLAMMATORY GENES MODIFY THE PHENOTYPE OF SEVERE HEMOPHILIA A AND B
|
| Giridhara Rao J., Viswabandya A., Nair S., Poonoose P., Cherian S., Devadharshini M., Padankatti S., Shaji R., Mathews V., Chandy M., Srivastava A. |
| |
|
POLYMORPHISMS IN COAGULATION FACTORS ARE NOT ASSOCIATED WITH THE RISK OF RECURRENT MAJOR ARTERIAL CARDIOVASCULAR EVENTS IN MEN AFTER A FIRST MYOCARDIAL INFARCTION: RESULTS OF 11 YEARS FOLLOW-UP
|
| van der Krabben M.D., Doggen C.J.M., van der Bom J.G., Rosendaal F.R. |
| |
|
POLYMORPHISMS IN THE 3'-END OF THE FIBRINOGEN GAMMA GENE AND RISK OF VENOUS THROMBOEMBOLISM IN THE AFRICAN-AMERICAN AND CAUCASIAN POPULATION
|
| Uitte de Willige S., Pyle M.E., Vos H.L., de Visser M.C.H., Lally C., Dowling N.F., Hooper W., Bertina R.M., Austin H. |
| |
|
POLYMORPHISMS IN THE IL6 GENE IN FAMILIES WITH EARLY-ONSET CORONARY ARTERY DISEASE (CAD) -INDIAN ATHEROSCLEROSIS RESEARCH STUDY
|
| Maitra A., Ganapathy P., Debabratha D., Rao V.S., Natesha B.K., Mukherjee M., Kakkar V.V. |
| |
|
POLYMORPHISMS OF VON WILLEBRAND FACTOR (VWF) GENE PROMOTER MODULATE THE CORTICOSTEROID-MEDIATED INCREASE IN VWF LEVELS IN CUSHING'S SYNDROME: A POTENTIAL MODEL OF TRANSCRIPTIONAL REGULATION AND A NEW THROMBOTIC MARKER
|
| Daidone V., Sartorello F., Sztukowska M., Albiger N., Scaroni C., Mantero F., Pagnan A., Casonato S. |
| |
|
POLYPHOSPHATE ENHANCES FACTOR XII ACTIVATION
|
| Mutch N.J., Choi S., Morrissey J.H. |
| |
|
POLYPHOSPHATE INTERACTS WITH THROMBIN EXOSITE II WITH HIGH AFFINITY
|
| Mutch N.J., Myles T., Leung L.L.K., Morrissey J.H. |
| |
|
PORT IS NOT A SAFE AND SUITABLE VENOUS ACCESS FOR IMMUNE TOLERANCE TREATMENT (ITT) IN HEMOPHILIC CHILDREN
|
| Mancuso M.E., Santagostino E., Siboni S.M., Mannucci P.M. |
| |
|
PORT--CATH-RELATED THROMBOSIS AND POSTTHROMBOTIC SYNDROME IN PAEDIATRIC ONCOLOGY PATIENTS: THE PACTOP STUDY
|
| Albisetti M., Kellenberger C., Bergstraesser E., Huisman T.A., Niggli F., Schmugge M. |
| |
|
POSSIBLE INVOLVEMENT OF CD226 IN CELLULAR INTERACTION OF MEGAKARYOCYTES WITH ENDOTHELIAL CELLS DURING MEGAKARYOPOIESIS AND PLATELET PRODUCTION
|
| Yuki S., Kojima H., Kozuma Y., Nagasawa T., Shibuya K., Shibuya A. |
| |
|
POSSIBLE MECHANISMS OF THE DEVELOPMENT OF DIC SYNDROME
|
| Kuznik B.I., Alfonsova E.V., Vitkovsky Y.A., Tsybikov N.N. |
| |
|
POSSIBLE PLACEMENT OF THE ELUSIVE TAIL OF HEPARIN COFACTOR II REVEALED BY A CRYSTAL STRUCTURE AT LOW IONIC STRENGTH
|
| Nakamura G., Langdown J., Huntington J.A. |
| |
|
POST - CORONARY INTERVENTION RECURRENT ISCHEMIA IN THE PRESENCE OF ADEQUATE PLATELET INHIBITION BY DUAL ANTIPLATELET THERAPY: WHAT ARE WE OVERLOOKING?
|
| Gurbel P.A., Bliden K.P., Navickas I., Cohen E., Tantry U.S. |
| |
|
POST-INFECTIOUS PURPURA FULMINANS (PF): 12 YEAR-EXPERIENCE AT A SINGLE ARGENTINEAN CENTER
|
| Bonduel M.M., Hepner M.D., Pieroni G., Sciuccati G.B., Feliú Torres A., Castañón M., Frontroth J.P. |
| |
|
POSTMARKETING SURVEILLANCE STUDY OF SUCROSE-FORMULATED RECOMBINANT FACTOR VIII FOR SEVERE HEMOPHILIA A: FINAL RESULTS
|
| Musso R., Santagostino E., Faradji A., Maas-Enriquez M. |
| |
|
POSTPARTUM LOCHIAL LOSS IN WOMEN WITH INHERITED BLEEDING DISORDERS
|
| Chi C., Lee C.A., Kadir R.A. |
| |
|
POST-THROMBOTIC SYNDROME (PTS) AFTER TOTAL HIP REPLACEMENT (THR): INCIDENCE AND CORRELATES
|
| Mant M.J., Eurich D.T., Russell D.B., Majumdar S.R. |
| |
|
POST-THROMBOTIC SYNDROME (PTS) SIGNS AND SYMPTOMS AT THE TIME OF DISCONTINING 5-7 MONTHS OF ORAL ANTICOAGULANT (OAC) THERAPY FOR IDIOPATHIC VENOUS THROMBOEMBOLISM (VTE) IS ASSOCIATED WITH SUBSEQUENT RECURRENT VTE
|
| Rodger M.A., Kovacs M.J. |
| |
|
POST-THROMBOTIC SYNDROME AFTER VENA CAVA FILTER PLACEMENT: A SYSTEMATIC REVIEW
|
| Fox M.A., Kahn S.R. |
| |
|
POST-THROMBOTIC SYNDROME IN CHILDREN SURVIVING ACUTE LYMPHOBLASTIC LEUKEMIA
|
| Kuhle S., Spavour M., Massicotte P., Halton J., Cherrick I., Dix D., Mahony D., Desai S., Mitchell L.G. |
| |
|
POST-TREATMENT PLATELET FUNCTION PREDICTS MYOCARDIAL INJURY IN ACUTE MYOCARDIAL INFARCTION PATIENTS UNDERGOING PRIMARY PCI
|
| Marcucci R., Paniccia R., Gori A., Antonucci E., Romano E., Poli S., Giglioli C., Prisco D., Gensini G., Abbate R. |
| |
|
POTENT ANTITHROMBOTIC ACTIVITY OF APIXABAN, A DIRECT FACTOR XA INHIBITOR, WITH MINIMUM BLEEDING TIME EFFECT IN RABBIT MODELS OF ARTERIAL THROMBOSIS AND HEMOSTASIS
|
| Wong P.C., Watson C.A., Crain E.J., Ogletree M.L., Wexler R.R., Lam P.Y.S., Pinto D.J., Knabb R.M. |
| |
|
POTENT INHIBITION OF PDGF-BB-STIMULATED RESPONSES IN VASCULAR SMOOTH MUSCLE CELL PROLIFERATION BY CUDRATRICUSXANTHONE A ISOLATED FROM THE ROOT BARK OF CUDRANIA TRICUSPIDATA
|
| Kim T., Han H., Seo J., Hong S., Hwang J., Hwang B., Lee J., Yu J., Shin H., Yun Y. |
| |
|
POTENTIAL FACTORS WHICH MAY CAUSE A HIGH LEVEL OF ACA IGG AND IGM
|
| Djumhana Atmakusuma T., Reksodiputro A., Tambunan K., Setyaningsih I., Pattanapanyasat K., Doulsri E. |
| |
|
POTENTIAL OF THE FACTOR XA INHIBITOR RIVAROXABAN FOR THE ANTICOAGULATION MANAGEMENT OF PATIENTS WITH HEPARIN-INDUCED THROMBOCYTOPENIA
|
| Walenga J.M., Jeske W.P., Prechel M., Hoppensteadt D., Swank J., Sheen L., Misselwitz F., Messmore H., Bakhos M. |
| |
|
POTENTIAL ROLE OF ADAMTS13/FXI COMPLEXES IN THE PATHOGENESIS OF ESRD
|
| Fareed J., Hoppensteadt D., Cunanan J., Patel C., Bajwa R.S., Maddineni J., Baltasar F., Bansal V. |
| |
|
POTENTIAL ROLE OF RAPID MOLECULAR SCREENING OF PATIENTS WITH DYSFIBRINOGENEMIA
|
| Hill M., Krishnamurthy S., Nicholson E., Tait R., Dolan G. |
| |
|
POTENTIAL USE OF AUTOMATED THROMBIN CLOTTING TIME (TCT) ASSAY FOR MONITORING UFH THERAPY
|
| Newall F., Ignjatovic V., Johnston L., Summerhayes R., Monagle P. |
| |
|
POTENTIAL USE OF LIGANDS TO FVIII INHIBITORS
|
| Kessel C., Kreuz W., Klich K., Becker K., Vorpahl F., Königs C. |
| |
|
POTENTIALLY PRO-THROMBOTIC ASSOCIATIONS BETWEEN PLATELET AND ENDOTHELIAL FUNCTION IN PATIENTS WITH PERIPHERAL ARTERIAL DISEASE
|
| Ford I. |
| |
|
PR-15 A NOVEL INTRAVENOUS INHIBITOR OF PLATELET ADHESION: A PHASE I DOSE ASCENDING PHARMACOKINETIC, PHARMACODYNAMIC, AND TOLERANCE STUDY
|
| Combe S., Rosport K., Kennedy A. |
| |
|
PRACTICE PATTERNS IN PREVENTION OF VENOUS THROMBOEMBOLISM IN PRIMARY TOTAL HIP ARTHROPLASTY PATIENTS
|
| Hitos K., Fletcher J.P. |
| |
|
PREANALYTICAL CONDITIONS INFLUENCING FLOW CYTOMETRIC DETERMINATION OF PLATELET-DERIVED MICROPARTICLES (PDMP)
|
| Mobarrez F., Antovic J., Wallén H., Egberg N. |
| |
|
PREANALYTICAL VARIABLES IN THE FLOW CYTOMETRIC ANALYSIS OF MICROPARTICLES
|
| Enjeti A.K., Lincz L., Seldon M. |
| |
|
PRECLINICAL PHARMACOLOGY OF AV513 INCLUDING ORAL EFFICACY IN SEVERE HEMOPHILIA A DOGS
|
| Prasad S., Labelle A., Powell S., Burnett E., Knappe S., Patarroyo-White S., Johnson K.W., Lillicrap D. |
| |
|
PREDICTING RISK OF RECURRENT VENOUS THROMBOSIS USING A 5-POINT SCORING SYSTEM INCLUDING FIBRIN D-DIMER
|
| Tait R.C., Lowe G.D.O., McColl M.D., McMahon A.D., Robertson L., King L., Clarke S., Conkie J., Roditi G.H., Walker I.D. |
| |
|
PREDICTION OF BLEEDING AND THROMBOTIC EVENTS IN PATIENTS WITH MECHANICAL HEART VALVE PROSTHESES TREATED WITH ORAL ANTICOAGULANTS
|
| van Leeuwen Y., Cannegieter S.C., Rosendaal F.R. |
| |
|
PREDICTION OF PRIMARY HEMOSTATIC DEFECT TYPE AND SEVERITY WITH THE PFA-100 CLOSURE TIME
|
| Gudmundsdottir B.R., Agustsdottir M., Onundarson P.T. |
| |
|
PREDISPOSING FACTORS IN PATIENTS WITH EARLY-ONSET CEREBRAL VEIN THROMBOSIS
|
| Tufano A., Di Capua M., Coppola A., Macarone Palmieri N., Guida A., Somma C., Fiorica A., Cirillo F., Cerbone A.M., Di Minno G. |
| |
|
PREFERENCES TOWARDS COAGULATION FACTOR CONCENTRATES USED TO TREAT HEMOPHILIC PATIENTS WITH INHIBITORS: THE PATIENTS', PHYSICIANS' AND PHARMACISTS' PERSPECTIVE
|
| Scalone L., Borghetti F., Gringeri A., Mantovani L., v. Mackensen S. |
| |
|
PREGNANCY ASSOCIATED ALTERATIONS OF THE INFLAMMATORY MEDIATORS, TISSUE FACTOR PATHWAY INHIBITOR AND PROTEIN Z
|
| Lavin J., Hoppensteadt D., Cunanan J., Gianopoulos J., Fareed J. |
| |
|
PREGNANCY MORBIDITY IS ASSOCIATED WITH LOW PLASMA TISSUE FACTOR PATHWAY INHIBITOR LEVELS, INCREASED THROMBIN GENERATION AND RESISTANCE TO ACTIVATED PROTEIN C
|
| Gardiner C., Cohen H., Machin S.J., Mackie I.J. |
| |
|
PREGNANCY OUTCOME IN WOMEN WITH THE LUPUS ANTICOAGULANT AND A HISTORY OF THROMBOEMBOLISM (TE)
|
| Alguel G., Kostova G., Koder S., Vormittag R., Simanek R., Kurz C., Pabinger I. |
| |
|
PREGNANT HEREDITARY ANTITHROMBIN DEFICIENT WOMEN REQUIRE A DISTINCT DOSING STRATEGY FOR THE MANAGEMENT OF AT ACTIVITY LEVELS WITH ANTITHROMBIN ALFA
|
| Frieling J.T.M., Drenth H.J., Bonfiglio J., Tait R.C. |
| |
|
PRELIMINARY PERFORMANCE DATA OF A NEW QUANTITATIVE AND SENSITIVE D-DIMER ASSAY
|
| Wissel T., Kraul D., Pilgrim S., Zander N. |
| |
|
PRELIMINARY RESULTS FROM EUROCLOT: HERITABILITY AND LINKAGE PEAKS FOR D-DIMER AND FIBRINOLYSIS TIME
|
| Cherkas L.F., Williams F.M.K., Carter A., Kato B., Falchi M., Grant P.J., Spector T.D. |
| |
|
PRELIMINARY RESULTS ON EFFECTIVENESS AND SAFETY OF COMBINED ANTICOAGULANT AND ANTIPLATELET THERAPY
|
| Laiou E., Anastasopoulou I., Kotsi P., Tsoucala C., Markakis K., Karafoulidou A. |
| |
|
PRENATAL DIAGNOSIS OF HAEMOPHILIA A BY USING INTRON 1 INVERSION MUTATION
|
| Tagariello G., Salviato R., Belvini D., Radossi P., Sartori R., De Biasi E., Pietrobon F., Zanotto D., Tassinari C., Di Gaetano R. |
| |
|
PRESERVATION OF IN VITRO FUNCTION OF PLATELETS STORED IN THE PRESENCE OF A SYNTHETIC DUAL INHIBITOR OF FACTOR XA AND THROMBIN
|
| Hellstern P., Stürzebecher U., Vogt A., Stürzebecher J. |
| |
|
PRETERM BIRTH AND FETAL GROWTH RESTRICTION HAVE AN IMPACT ON ELASTIC AND COLLAGENIC STRUCTURES OF HUMAN UMBILICAL ARTERIES
|
| Lamy E., Tauzin L., Risso F., Chareyre C., Charpiot P., Simeoni U., Dignat-George F. |
| |
|
PREVALENCE AND DISTRIBUTION OF DEEP VEIN THROMBOSIS IN PATIENTS WITH SYMPTOMATIC PULMONARY EMBOLISM
|
| Ochi M., Yamaki T., Nozaki M., Sakurai H., Takeuchi M., Soejima K., Kono T. |
| |
|
PREVALENCE OF "ASPIRIN RESISTANCE" IN CHILDREN
|
| Yee D.L., Dinu B., Sun C., Teruya J., Edwards R.M., Bray P.F., Bomgaars L.R. |
| |
|
PREVALENCE OF APOLIPOPROTEIN E ALLELES AND ITS ASSOCIATION WITH SERUM LIPID LEVELS IN BRAZILIAN PATIENTS WITH ISCHEMIC STROKE AND PERIPHERAL ARTERIAL DISEASE
|
| Sabino A.P., Carvalho M.G., Souza M.O., Ribeiro D.D., Lima L.M., Domingheti C.P., Paiva S.G., Dusse L.M.S., Fernandes A.P.S.M. |
| |
|
PREVALENCE OF ASPIRIN RESISTANCE MEASURED BY TWO RAPID PLATELET FUNCTION ANALYZERS
|
| Cho Y., Chi H., Jang S., Park C., Park D., Jeong Y., Park S. |
| |
|
PREVALENCE OF CROSS-REACTIVE EPITOPES TO BOVINE FACTOR VA LIGHT CHAIN FRAGMENTS IN NORMALS AND END STAGE RENAL DISEASE PATEINTS
|
| Hoppensteadt D., Bansal V., Cunanan J., Patel K., Wahi R., Fareed J. |
| |
|
PREVALENCE OF DEEP VENOUS THROMBOSIS IN A YEAR AFTER THE MID NIIGATA PREFECTURE EARTHQUAKE
|
| Hanzawa K., Fuse I., Nakajima T., Okamoto T., Sato K., Aizawa Y., Hayashi J. |
| |
|
PREVALENCE OF DEEP VENOUS THROMBOSIS OR PULMONARY EMBOLISM (DVT/PE) IN PSYCHIATRY PATIENTS
|
| Hanzawa K., Okamoto T., Sato K., Hayashi J., Toyooka K. |
| |
|
PREVALENCE OF FACTOR V LEIDEN, PROTHROMBIN G20210A, AND 5,10-METHYLENETETRAHYDROFOLATE REDUCTASE C677T GENE MUTATIONS IN A HEALTHY RUSSIAN POPULATION
|
| Kalashnikova E.A., Kokarovtseva S.N., Sirotkina O.V., Sheydina A.M., Kovalenko T.F., Patrushev L.I. |
| |
|
PREVALENCE OF HEPATITIS B AND C AND ABNORMAL LIVER FUNCTION TESTS IN PATIENTS WITH HEMOPHILIA IN KOREA
|
| Choi K., Kim M. |
| |
|
PREVALENCE OF HYPERHOMOCYSTEINEMIA IN WOMEN WITH PREMENSTRUAL SYNDROME AND EFFECT OF ORAL AND VAGINAL DELIVERY OF ETHINYL ESTRADIOL AND DEZOGESTREL ON HOMOCYSTEINE LEVELS
|
| Shmeleva V.M., Slivankova E.V., Aganezova N.V., Tatarova N.N. |
| |
|
PREVALENCE OF POLYMORPHISMS IN EXONS 6 E 7 OF ABO LOCUS AND THEIR ASSOCIATION WITH VENOUS THROMBOSIS IN YOUNG BRAZILIAN PATIENTS
|
| Paiva S.G., Carvalho M.G., Sabino A.P., Ribeiro D.D., Braga K.G., Sousa M.O., Dusse L.M.S., Fernandes A.P.S.M. |
| |
|
PREVALENCE OF PROTEIN S (PS), PROTEIN C (PC), ANTITHROMBIN (AT) DEFICIENCY AND ACTIVATED PC RESISTANCE (APC-R) IN THE CHINESE POPULATION
|
| Zhao Y., Zhu T., Kaguelidou F., Hua B., Yang R., Wang X., Wang H., Wang X., Ding Q., Wei X., Ruan C., Wang Z., Bai X., Schlegel N. |
| |
|
PREVALENCE OF THROMBOPHILIA IN WOMEN WITH PREGNANCY LOSS AND GESTATIONAL OUTCOME IN WOMEN WITH DIAGNOSED THROMBOPHILIA FOLLOWING ANTITHROMBOTIC THERAPY
|
| Shmeleva V.M., Kapustin S.I., Alabieva E.A., Plughnikova T.A. |
| |
|
PREVALENCE OF THROMBOPHILIA IN WOMEN WITH RECURRENT PREGNANCY LOSS SERBIAN EXPERIENCE
|
| Mikovic D., Kovac M., Djodjevic V., Rakicevic L., Rakic L., Maslac A., Radojkovic D. |
| |
|
PREVALENCE OF UNPROVOKED VENOUS THROMBOEMBOLISM AND OF TRANSIENT AND PERMANENT RISK FACTORS IN DIFFERENT AGE GROUPS: RESULTS OF THE MASTER REGISTRY
|
| Ageno W., Agnelli G., Imberti D., Moia M., Palareti G., Pistelli R., Rossi R., Verso M. |
| |
|
PREVALENCE OF VON WILLEBRAND'S DISEASE IN PREMENOPAUSAL WOMEN WITH IRON DEFICIENCY ANEMIA AND MENORRHAGIA
|
| Chen Y., Cheng S., Chao T., Tsai W., Hu S., Chiang J., Huang S. |
| |
|
PREVENTION OF RECURRENT THROMBOEMBOLISM BY ADJUSTING THE DURATION OF ANTICOAGULATION ACCORDING TO RESIDUAL VEIN THROMBOSIS. A RANDOMIZED STUDY
|
| Prandoni P., Lensing A.W.A., Prins M.H., Ghirarduzzi A., Ageno W., Imberti D., Villalta S., Parisi R., Pesavento R., Cuppini S., Quintavalla R., Agnelli G. |
| |
|
PREVENTION OF TRAVELLERS' THROMBOSIS: A COMPARISON OF THREE INTERVENTIONS THAT PROMOTE VENOUS OUTFLOW
|
| Coppens M., Schreijer A.J.M., Berger F.H., Cannegieter S.C., Rosendaal F.R., Büller H.R. |
| |
|
PREVENTION OF VENOUS THROMBOEMBOLISM VIA PARTIAL FACTOR IXA INHIBITION
|
| Eriksson B.I., Dahl O.E., Lassen M.R., Ward D.P., Rothlein R., Davis G., Turpie A.G.G. |
| |
|
PRIMARY HEMOSTATIC EFFICACY OF RVWF IN A NOVEL MODEL OF VASCULAR INJURY IN MICE WITH SEVERE VWF DEFICIENCY
|
| Baumgartner B., Eder B., Muchitsch E.M., Turecek P.L., Gritsch H., Fesl E., Schwarz H.P. |
| |
|
PRIMARY HUMAN SYNOVIAL CELLS PROLIFERATE IN RESPONSE TO HEMOGLOBIN AND WHOLE BLOOD
|
| Valentino L.A., Gruber F., Hakobyan N., Enockson C., Han W. |
| |
|
PRIMARY KNEE ARTHOPLASTY USING RECOMBINANT FACTOR VIIA (RFVIIA) AS FIRST-LINE THERAPY IN HAEMOPHILIA PATIENTS WITH HIGH RESPONDING INHIBITORS
|
| Laurian Y.D., Tagariello G., Jimenez Yuste V., Kurth A., Lambert T., Nunez R., Goddard N., Morfini M. |
| |
|
PRIMARY PROPHYLAXIS WITH RECOMBINANT FACTOR VIIA IN A PATIENT WITH HAEMOPHILIA A AND INHIBITOR
|
| Molina M.Q., Salces M.M., Yuste V.J., Román M.A., Garrido J.R., Bello I.F., Navarro F.H. |
| |
|
PRION PROTEIN (PRPSC) REMOVAL BY CHROMATOGRAPHY PURIFICATION AND NANOFILTRATION OF FIXS AND PCC
|
| Neisser-Svae A., Hoffer L., Biesert L., Schmidt T., Roemisch J., Svae T. |
| |
|
PRION PROTEIN REMOVAL DURING MANUFACTURING OF HIGH-PURITY VWF/FVIII CONCENTRATES
|
| Neisser-Svae A., Gruber G., Stadler M., Biesert L., Schmidt T., Roemisch J., Svae T. |
| |
|
PRO- AND ANTI-ANGIOGENIC CYTOKINES ARE CONDITIONALLY AND SELECTIVELY RELEASED FROM ALPHA-GRANULES UPON PLATELET STIMULATION
|
| Brill A., Zelikovitz T., Shlomai G., Kalchenko V., Varon D. |
| |
|
PROBING THE BETA-CHAIN HOLE OF FIBRINOGEN WITH SYNTHETIC PENTAPEPTIDES THAT DIFFER ONLY AT THEIR AMINO TERMINI
|
| Doolittle R.F., Pandi L. |
| |
|
PROBING THE ORIGINS OF ACTIVITY ENHANCEMENT IN FACTOR VIIA (FVIIA) VARIANTS BY HYDROGEN EXCHANGE MASS SPECTROMETRY (HX-MS)
|
| Rand K.D., Olsen O.H., Andersen M.D., Stennicke H.R., Persson E. |
| |
|
PROCARBOXYPEPTIDASE U (TAFI) PLASMA LEVELS IN PATIENTS WITH HEREDITARY THROMBOPHILIA
|
| Willemse J.L., Miljic P., Heylen E., Hendriks D. |
| |
|
PROCOAGULANT EFFECT OF DEXAMETHASONE IN HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS: A POTENTIAL MECHANISM OF GLUCOCORTICOID-INDUCED OSTEONECROSIS
|
| Kerachian M., Cournoyer D., Chow T.Y.K., Harvey E.J., Séguin C. |
| |
|
PROCOAGULANT EFFECTS OF NEOADJUVANT CHEMORADIATION FOR OESOPHAGEAL CANCER
|
| Byrne M., Byrne M., O'Donnell J., White B., Reynolds J.V. |
| |
|
PRODUCT FEATURES OF THE NOVEL GENERATION VWF/FVIII CONCENTRATE IN A COMPARISON WITH FIRST GENERATION PRODUCTS
|
| Pock K., Stadler M., Gruber G., Kannicht C., Roemisch J., Svae T. |
| |
|
PRODUCTION AND CHARACTERIZATION OF MONOCLONAL ANTIBODIES AGAINST THE B SUBUNIT OF FACTOR XIII THAT INHIBIT THE FORMATION OF HETEROTETRAMERIC COMPLEX OF A AND B SUBUNITS
|
| Katona É., Csapó A., Szabó I., Haramura G., Muszbek L. |
| |
|
PROGNOSTIC FACTORS OF SHORT-TERM SURVIVAL IN PATIENTS WITH DEEP VEIN THROMBOSIS: FINDINGS FROM A PROSPECTIVE REGISTRY (RIETE)
|
| Grau E., Tenias J., Soto M., Gutierrez M., Lecumberri R., Perez J., Tiberio G. |
| |
|
PROGNOSTIC SIGNIFICANCE FOR VENOUS THROMBOEMBOLISM (VTE) OF HEMOSTATIC MARKERS IN PATIENTS WITH MULTIPLE MYELOMA (MM) RECEIVING THALIDOMIDE
|
| Falanga A., Russo L., Vignoli A., Balducci D., Marchetti M., Barbui T., Galli M. |
| |
|
PROGNOSTIC SIGNIFICANCE OF MRD (MINIMAL RESIDUAL DISEASE) QUANTIFICATION BY PCR IN CHILDHOOD ACUTE LEUKEMIA
|
| Elbaz O., Mansour A., Abd El-Kader A., El-Menshawi N., El-Demery A. |
| |
|
PROGNOSTIC SIGNIFICANCE OF THE POLYMORPHISMS IN METHYLENETETRAHYDROFOLATE REDUCTASE (MTHFR C677T) AND THYMIDYLATE SYNTHASE ENHANCER REGION (TSER) GENE IN EPILEPSY
|
| Kim N., Kim O., Han I., Lee I., Park H., Bae S. |
| |
|
PROGNOSTIC VALUE OF TROPONINS IN ACUTE PULMONARY EMBOLISM: A META-ANALYSIS
|
| Becattini C., Vedovati M.C., Agnelli G. |
| |
|
PROGRAMMED ANUCLEAR CELL DEATH DELIMITS PLATELET LIFE SPAN
|
| Mason K.D., Metcalf D., Roberts A.W., Huang D.C.S., Kile B.T. |
| |
|
PROGRAMMED AUTOLOGOUS CLEAVAGE OF PLATELET RECEPTORS
|
| Berndt M.C., Gardiner E.E., Andrews R.K., Karunakaran D. |
| |
|
PROGRESS AND HURDLES IN NOVEL GENETIC THERAPIES FOR HEMOPHILIA
|
| High K.A. |
| |
|
PROLONGED DVT PROPHYLAXIS IS BETTER THAN STANDARD PROPHYLAXIS IN MAJOR ABDOMINAL SURGERY: A META-ANALYSIS
|
| Bottaro F., Ceresetto J.M., Emery N., Bruetman J., Duboscq C., Doti C., Stemmelin G., Rabinovich O., Shanley C., Bullorsky E. |
| |
|
PROLONGED HEMOSTATIC ABILITY OF POLY(ETHYLENE GLYCOL)-MODIFIED POLYMERIZED ALBUMIN PARTICLES CARRYING FIBRINOGEN-GAMMA CHAIN DODECAPEPTIDE
|
| Fujie T., Okamura Y., Handa M., Ikeda Y., Takeoka S. |
| |
|
PRONOUNCED B KNOB CAPACITY TO MODULATE FIBRIN ARCHITECTURE, STIFFNESS, AND PLASMIN LYSIS
|
| Galanakis D.K., Neerman-Arbez M.M., Sheiner T., Hubbs-Taan D., Nagaswami C., Henschen A., Weisel J. |
| |
|
PROPHYLACTIC APPROACH TO WOMEN WITH THROMBOPHILIA AND REPEATED SPONTANEOUS ABORTIONS
|
| Mitic G., Filipov P., Povazan L., Canak V., Maticki M., Novakov Mikic A., Lucic A.M. |
| |
|
PROPHYLAXIS OF RECURENT PREECLAMPSIA IN PATIENTS WITH THROMBOPHILIA
|
| Bitsadze V.O., Makatsariya A.D., Baimuradova S.M., Akinshina S.V. |
| |
|
PROPHYLAXIS OF THROMBOEMBOLIC COMPLICATIONS IN PREGNANT WOMEN WITH THROMBOPHILIA
|
| Akinshina S.V., Makatsariya A.D., Bitsadze V.O., Baimuradova S.M. |
| |
|
PROPHYLAXIS WITH RECOMBINANT FVIIA
|
| Molina M.Q., Bello I.F., Yuste V.J., Román M.A., Salces M.M., Garrido J.R., Navarro F.H. |
| |
|
PROPOSITION FOR A MULTI-STEP MUTATION DETECTION IN HAEMOPHILIA A
|
| Lannoy N., Abinet I., Verellen C., Vermylen C., Hermans C., Dahan K. |
| |
|
PROS1 ANALYSIS IN 87 PEDIGREES WITH HEREDITARY PROTEIN S DEFICIENCY DEMONSTRATES STRIKING GENOTYPE-PHENOTYPE ASSOCIATIONS
|
| ten Kate M.K., Platteel M., Mulder R., Nicolaes G.A.F., van der Steege G., van der Meer J. |
| |
|
PROSPECTIVE DESIGN OF A NEW, OBJECTIVE SCORING SYSTEM FOR IDENTIFYING DISSEMINATED INTRAVASCULAR COAGULATION IN DOGS A SPONTANEOUS ANIMAL MODEL
|
| Wiinberg B., Jensen A.L., Kjelgaard-Hansen M., Johansson P.I., Tranholm M., Kristensen A.T. |
| |
|
Prospective Evaluation of a Quantitative D-dimer for Pulmonary Embolism: is Structured Pretest Probability Assessment Always Needed?
|
| Courtney D.M., McCormick J.C., Steinberg J.M. |
| |
|
PROSPECTIVE EVALUATION OF A SIMPLIFIED SCORE FOR THE PREDICTION OF DISSEMINATED INTRAVASCULAR COAGULATION IN SEPSIS
|
| Lissalde-Lavigne G., Combescures C., Dorangeon E., Muller L., Bengler C., Lefrant J.Y., Gris J.C. |
| |
|
PROSPECTIVE EVALUATION OF LABORATORY TESTS FOR THE DIAGNOSIS OF HEPARIN-INDUCED THROMBOCYTOPENIA
|
| Francis J.L., Drexler A., Duncan M., Desai H., Amaya M., Robson T., Meyer T.V., Reyes E., Amirkhosravi A. |
| |
|
PROSPECTIVE POST LICENSURE SURVEILLANCE OF EFFICACY AND TOLERABILITY OF A HIGH PURITY, DOUBLE VIRUS INACTIVATED VWF/FVIII CONCENTRATE IN THE TREATMENT OF VON WILLEBRAND'S DISEASE
|
| Nowak-Göttl U., Auerswald G., Feddern J., Großmann R., Kadar J., Klamroth R., von Depka M., Wermes C. |
| |
|
PROSPECTIVE, RANDOMIZED OPEN TRIAL OF ENOXAPARIN IN PATIENTS WITH ADVANCED PANCREATIC CANCER UNDERGOING FIRST-LINE CHEMOTHERAPY
|
| Pelzer U., Oettle H., Stauch M., Opitz B., Stieler J., Scholten T., Riess H. |
| |
|
PROSTACYCLIN IMPROVES TRANSCORONARY MYOCARDIAL DELIVERY OF ADIPOSE TISSUE-DERIVED STROMAL CELLS
|
| Madonna R., Rinaldi L., Rossi C., Geng Y., De Caterina R. |
| |
|
PROTEASE NEXIN-1 AND THROMBOMODULIN FORM COMPLEXES WITH A HIGHLY POTENT ANTI-THROMBIN ACTIVITY
|
| Bouton M.C., Venisse L., Richard B., Arocas V., Jandrot-Perrus M. |
| |
|
PROTEASE-ACTIVATED RECEPTOR 2 (PAR-2) A NOVEL TARGET TO PREVENT FIX INHIBITOR FORMATION
|
| Baila S., Furlan Freguia C., Favaro P., Schuettrumpf J., Mingozzi F., Andrade-Gordon P., Arruda V. |
| |
|
PROTEASE-ACTIVATED RECEPTORS IN HEALTH AND DISEASE
|
| Coughlin S.R. |
| |
|
PROTEIN C ACTIVATOR (PCA) INTERRUPTION OF THROMBUS PROPAGATION WITHOUT ANTIHEMOSTATIC SIDE EFFECT IN PRIMATES
|
| Gruber A., Marzec U.M., Bush L., Tucker E.I., McCarty O.T.J., Hanson S.R., Di Cera E. |
| |
|
PROTEIN C ACTIVATOR (PCA) TREATMENT IMPROVES THE NEUROLOGICAL OUTCOME OF EXPERIMENTAL THROMBOTIC ISCHEMIC STROKE IN MICE
|
| Gruber A., Hurn P.D., Hurst S., Bush L., Tucker E.I., Hanson S.R., Di Cera E. |
| |
|
PROTEIN C- CONCENTRATE BY SEPSIS WITH PURPURA FULMINANS
|
| Hofmann M., Hofmann K. |
| |
|
PROTEIN C IN PATIENTS WITH METABOLIC SYNDROME
|
| Oganova E.G. |
| |
|
PROTEIN C MUTATIONS IN THAI PATIENTS WITH VENOUS THROMBOEMBOLISM
|
| Chumpia W., Angchaisuksiri P., Choowongkomon K., Fucharoen S. |
| |
|
PROTEIN DISULFIDE ISOMERASE (PDI) UNCOVERS TISSUE FACTOR (TF)-DEPENDENT FIBRIN FORMATION AFTER VESSEL INJURY
|
| Grahl L., von Bruehl M., Reinhardt C., Manukyan D., Altmann B., Dlugai S., Konrad I., Lorenz M., Mackman N., Massberg S., Engelmann B. |
| |
|
PROTEIN S (PS) CONTAINS ZINC THAT IS ESSENTIAL FOR DIRECT ANTICOAGULANT ACTIVITY
|
| Heeb M.J., Prashun D., Bouma B.N. |
| |
|
PROTEIN S DEFICIENCY IN HIV INFECTED PEDIATRIC PATIENTS ON ANTIRETROVIRAL THERAPY
|
| Shetty K. |
| |
|
PROTEIN S-C4BP COMPLEX STIMULATES ACTIVATED PROTEIN C-MEDIATED INACTIVATION AT R306 BUT INHIBITS INACTIVATION AT R506 IN FACTOR VA
|
| Maurissen L., Thomassen S., Nicolaes G., Dahlbäck B., Tans G., Rosing J., Hackeng T. |
| |
|
PROTEIN Z LEVEL AND GENE POLYMORPHISMS IN MYOCARDIAL INFARCTION IN THE YOUNG
|
| Le Cam-Duchez V., Soria C., Bal dit Sollier C., Borg J.Y., Esposito G., Montalescot G., Drouet L., Collet J.P. |
| |
|
PROTEIN Z PLASMA LEVELS IN DIFFERENT LOCALIZATIONS OF ATHEROSCLEROTIC DISEASE
|
| Sofi F., Cesari F., Capalbo A., Alessandrello Liotta A., Pratesi G., Troisi N., Pratesi C., Abbate R., Gensini G., Fedi S. |
| |
|
PROTEINOMIC PROFILING OF TISSUE FACTOR MEDIATED PROTHROMBIN ACTIVATION PRODUCTS AND THEIR INHIBITION BY DIRECT ANTITHROMBIN AND ANTI-XA AGENTS
|
| Florian M., Maddineni J., Zhu H., Hoppensteadt D., Jeske W.P., Fareed J. |
| |
|
PROTEOLYSIS-INDEPENDENT ENHANCEMENT OF ARTERIAL THROMBOSIS MEDIATED BY THROMBIN BINDING TO GLYCOPROTEIN IB AND VON WILLEBRAND FACTOR
|
| Mendolicchio L., Orje J.N., Roberts J.R., Ruggeri Z.M. |
| |
|
PROTEOLYTIC CLEAVAGE OF ACTIVATED COAGULATION FACTOR XIII BY PLASMIN: NOVEL MECHANISM OF FACTOR XIII REGULATION?
|
| Philippou H., Rice G.I., Adamson P.J., Grant P.J. |
| |
|
PROTEOLYTIC CONVERSION OF CLOTTING FACTOR XA INTO A FIBRINOLYSIS ACCELERATOR
|
| Pryzdial E.L.G., Meixner S.C., Talbot K. |
| |
|
PROTEOME OF ENDOTHELIAL CELL-DERIVED PROCOAGULANT MICROPARTICLES
|
| Brioschi M., Wait R., Mussoni L., Tremoli E., Banfi C. |
| |
|
PROTEOMIC ANALYSIS IN PLATELET DYSFUNCTION
|
| Nugent D.J., Birschbach K., Nakagawa P. |
| |
|
PROTEOMIC ANALYSIS OF PLASMA FROM HAEMOPHILIA A PATIENTS AFTER FACTOR VIII CONCENTRATE INFUSION
|
| Dai L., Rangarajan S., Mitchell M. |
| |
|
PROTEOMIC ANALYSIS OF PLATELET DETERGENT-RESISTANT MEMBRANES FROM HEALTHY HUMAN DONORS WITH "EXTREME-END" RESPONSES TO COLLAGEN-RELATED PEPTIDE AND ADP
|
| Maguire P.B., Foy M., Bernard A., Dudbridge F., Dunn R., Garner S., Jennings N., Jones C.I., Sullivan M., Walton J., Wynne K., Goodall A., Ouwehand W.H., Cagney G., Fitzgerald D.J. |
| |
|
PROTEOMIC ANALYSIS OF THE SHP-1 INTERACTOME IN HUMAN PLATELETS
|
| Jones M.L., Foy M., Steele B., Wynne K., Sullivan M., Clarke M., Cagney G., Fitzgerald D.J., Poole A.W., Maguire P.B. |
| |
|
PROTEOMICS OF CELL-BASED THERAPEUTICS - PROFILING OF ALTERATIONS IN PLATELET PROTEINS DURING STORAGE OF PLATELET CONCENTRATES
|
| Thiele T., Steil L., Gebhard S., Scharf C., Hammer E., Brigulla M., Lubenow N., Clemetson K.J., Völker U., Greinacher A. |
| |
|
PROTHROMBIN AND F1+2 LEVELS ARE SIGNIFICANTLY INCREASED IN SYMPTOMATIC COMPARED WITH ASYMPTOMATIC FAMILY MEMBERS CARRYING THE PROTHROMBIN G20210A MUTATION
|
| Medina P., Navarro S., Mira Y., Estellés A., Vayá A., Villa P., Ferrando F., Cubillo P., Bertina R.M., España F. |
| |
|
PROTHROMBIN AND FACTOR V LEIDEN GENE POLYMORPHISM IN PATIENTS WITH DVT
|
| Rizk A., El Naggar A.I., Saad I.M., Taha A., Mokhtar S. |
| |
|
PROTHROMBIN COMPLEX CONCENTRATE FOR REVERSAL OF ORAL ANTICOAGULATION THERAPY IN URGENT SITUATIONS. EXPERIENCE OF A SINGLE CENTER
|
| Carvalho M., Carneiro J., Monteiro C., Pereira R. |
| |
|
PROTHROMBIN TIME: COMPARISON BETWEEN DIFFERENT REAGENTS
|
| Paoletti O., Alatri A., Morstabilini G., Testa S. |
| |
|
PROTHROMBOTIC EFFECTS OF FIBRONECTIN ISOFORMS CONTAINING THE EDA DOMAIN
|
| Chauhan A.K., Kisucka J., Walsh M.T., Moretti F.A., Baralle F.E., Muro A.F., Wagner D.D. |
| |
|
PROTHROMBOTIC FACTORS AND OXIDATIVE STRESS MARKERS IN A TYPE 2 DIABETES POPULATION
|
| Barillari G., Fabbro E., Daminato R., Turello M., Bigotto E., Ceriello A. |
| |
|
PROTHROMBOTIC FACTORS IN INFANTS WITH NEONATAL CEREBRAL INFARCTION
|
| Barillari G., Bigotto E., Janes A., De Stasio G., Giacomello R., Maccagno F. |
| |
|
PRT060128, A NOVEL, DIRECT-ACTING ORALLY AVAILABLE P2Y12 ANTAGONIST, CONFERS SUPERIOR ANTITHROMBOTIC ACTIVITY OVER CLOPIDOGREL IN A MOUSE THROMBOSIS MODEL
|
| Andre P., Jurek M., Sim D., Deguzman F., Hollenbach S., Phillips D.R., Conley P.B. |
| |
|
P-SELECTIN (P-SEL) GENE HAPLOTYPES MODULATE SOLUBLE (S) P-SEL LEVELS AND INCREASE THE RISK OF VENOUS THROMBOEMBOLISM (VTE)
|
| Jungbauer L., Ay C., Kaider A., Koder S., Panzer S., Pabinger I., Mannhalter C. |
| |
|
PSEUDO-HOMOZYGOUS APC RESISTANCE DUE TO COINHERITANCE OF HETEROZYGOUS FACTOR V-R506Q AND FV TYPE I DEFICIENCY
|
| Pavlova A., Loreth R., Delev D., Oldenburg J. |
| |
|
PSGL1 AND LDL-RECEPTORS MEDIATE ADHESION OF LEUKOCYTES TO BETA2-GLYCOPROTEIN-I
|
| Pendu R., Weeterings C., Urbanus R.T., Pennings M.T.T., Denis C.V., de Groot P.G., Lenting P.J. |
| |
|
PSYCHOLOGICAL IMPACTS OF GENETIC TESTING FOR THROMBOPHILIA ON FIRST DEGREE RELATIVES OF PATIENTS WITH VENOUS THROMBOEMBOLISM AND A THROMBOPHILIA A PILOT STUDY
|
| Louzada M.L., Wells P.S., Dunn C.R., Langlois N., Wilson B., Kahn S.R., Rodger M.A., Anderson D.R., Kovacs M.J. |
| |
|
PT INR: COMPARISON BETWEEN TWO DIFFERENT POINT OF CARE SYSTEMS
|
| Paoletti O., Alatri A., Morstabilini G., Testa S. |
| |
|
PULMONARY EMBOLISM DIAGNOSTIC TOOLS IN FRENCH EMERGENCY DEPARTMENTS: AVAILABILITY INCREASES BUT PHYSICIAN KNOWLEDGE REMAINS POOR
|
| Roy P., Rodolphe B., Honnart D., Roupie E., Mazet B., Meyer G. |
| |
|
PULMONARY EMBOLISM FAILURE RATE IN PATIENTS IN WHOM PULMONARY EMBOLISM WAS RULED OUT BY LOW AND INTERMEDIATE PROBABILITY BY THE REVISED GENEVA SCORE AND A NORMAL QUANTITATIVE D-DIMER TEST RESULT
|
| Klok F.A., Karami Djurabi R., Nijkeuter M., Le Gal G., Perrier A., Huisman M.V. |
| |
|
PULMONARY EMBOLISM, OBESITY, DIABETES, AND HYPERTENSION AMONG AMERICAN CAUCASIANS IN THE GATE STUDY
|
| Hooper C., Lally C., Dowling N., Austin H. |
| |
|
PURIFIED A2 DOMAIN OF VWF BINDS TO THE ACTIVE CONFORMATION OF VWF AND BLOCKS THE INTERACTION WITH PLATELET GPIB; A NOVEL A2 DOMAIN-DERIVED PEPTIDE INHIBITS VWF-GPIB INTERACTION UNDER HIGH FLOW CONDITIONS
|
| Cruz M.A., Bergeron A., Dong J., Martin C. |
| |
